BIOA

In January 2026, BioAge completed an upsized follow-on public offering, raising approximately $132.3 million. In April 2026, BioAge reported positive topline data from the Phase 1 trial of BGE-102, showing significant hsCRP reductions. On May 8, 2026, BioAge reported its first-quarter 2026 financial results, highlighting increased collaboration revenue and larger operating loss due to increased development investments. As of April 28, 2026, the share price was $17.45, representing a significant increase from $4.33 on April 29, 2025, and as of May 9, 2026, the stock price was $17.99.